ORASURE TECHNOLOGIES INC OSUR

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are.

Our products and services reside under one reporting hierarchy, with commercial and innovation teams, which are part of a single business unit covering multiple product lines. Our business is principally comprised of the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions.

In November 2025, the Company acquired BioMedomics, Inc. ("BioMedomics"). BioMedomics' SickleSCAN® test is the world's first rapid point-of-care test for sickle cell disease. The SickleSCAN® test is currently sold in markets outside the U.S.

Last close 4.13 2026-10-23
Market cap $284.8M 2026-06-30 share count
52-week range 2.08 - 4.58

Valuation FY2025 figures against the last close

P/S2.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.94

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $115.0M$185.8M$405.5M$387.5M$233.7M$171.7M$154.6M$181.7M$167.1M$128.2M
Cost of revenue $66.8M$106.4M$233.8M$239.0M$116.1M$69.9M$60.0M$68.1M$68.1M$40.2M
Gross profit $48.2M$79.4M$171.7M$148.4M$117.6M$101.9M$94.6M$113.6M$99.0M$88.0M
R&D $42.5M$26.0M$33.7M$36.2M$34.2M$31.0M$19.6M$16.2M$13.4M$9.8M
SG&A $47.7M$46.2M$58.2M$68.2M$50.3M$42.7M$35.3M$38.3M$29.3M$28.4M
Total operating expenses $120.2M$107.6M$139.0M$170.6M$127.8M$107.0M$76.0M$85.2M$58.7M$67.8M
Operating income -$72.0M-$28.2M$32.7M-$22.2M-$10.2M-$5.2M$18.6M$28.4M$40.2M$20.3M
Pre-tax income -$64.6M-$16.0M$56.3M-$15.7M-$9.3M-$3.5M$21.3M$31.7M$41.0M$20.3M
Income tax $1.8M$1.8M$2.6M$1.5M$13.7M$11.4M$4.7M$11.3M$10.1M$603.0K
Net income -$68.7M-$19.5M$53.7M-$17.1M-$23.0M-$14.9M$16.7M$20.4M$30.9M$19.7M
EPS, basic -0.94-0.260.73-0.24-0.320.220.270.330.520.35
EPS, diluted -0.94-0.260.72-0.24-0.320.220.270.330.510.35
Shares, diluted (wtd. avg.) 73.5M74.4M74.4M72.5M72.0M67.5M62.2M62.5M61.0M56.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $199.3M$267.8M$290.4M$84.0M$116.8M$160.8M$75.7M$88.4M$71.0M$108.0M
Short-term investments ——$0$26.9M$36.3M$48.6M$80.6M$68.1M$83.0M$11.2M
Receivables $22.2M$23.8M$40.2M$70.8M$45.3M$38.8M$36.9M$34.8M$42.5M$19.8M
Inventory $31.1M$34.2M$47.6M$95.7M$53.1M$31.9M$23.2M$22.9M$19.3M$11.8M
Total current assets $261.9M$333.2M$386.5M$325.2M$299.3M$288.9M$224.6M$219.3M$221.9M$156.4M
Property, plant and equipment $39.2M$45.1M$45.4M$59.4M$73.4M$51.9M$30.3M$24.3M$21.4M$20.0M
Goodwill $43.4M$40.3M$35.7M$35.1M$40.3M$40.4M$36.2M$18.5M$20.1M$18.8M
Other intangibles $19.0M$17.4M$1.2M$11.7M$14.3M$17.9M$14.7M$5.1M$8.2M$10.3M
Total assets $403.2M$479.7M$482.8M$444.2M$461.0M$454.5M$349.3M$315.6M$296.2M$207.9M
Accounts payable $6.5M$8.2M$13.2M$38.0M$28.0M$17.4M$9.6M$10.6M$10.2M$4.6M
Total current liabilities $39.8M$33.5M$39.5M$69.1M$68.1M$46.5M$32.7M$28.0M$32.2M$17.3M
Total liabilities $62.3M$69.3M$52.2M$79.8M$80.5M$55.9M$42.1M$32.2M——
Retained earnings -$172.2M-$103.4M-$83.9M-$137.6M-$120.5M-$97.5M-$82.5M-$99.2M-$119.5M-$150.5M
Total equity $340.8M$410.3M$430.7M$364.4M$380.5M$398.6M$307.1M$283.4M$258.1M$185.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$49.0M$27.4M$141.6M-$47.2M-$35.4M$5.8M$9.8M$39.1M$28.2M$24.6M
Depreciation and amortisation $10.2M$10.9M$20.9M$15.3M$11.7M$9.4M$7.3M$6.5M$6.1M$5.7M
Stock-based compensation $10.1M$11.9M$10.7M$11.6M$7.8M$7.1M$4.1M$15.2M$7.0M$6.1M
Capital expenditure $4.2M$3.8M$5.8M$6.8M$21.9M$26.7M$9.3M$6.3M$4.3M$4.4M
Investing cash flow -$6.8M-$39.0M$66.2M$21.1M-$5.5M-$14.0M-$19.8M-$17.4M-$96.4M-$8.1M
Financing cash flow -$16.9M-$4.2M-$3.0M-$3.8M-$2.8M$92.5M-$4.7M-$1.9M$30.4M-$1.2M
Buybacks $15.0M$0$0$2.3M$2.1M$2.1M$3.7M$3.6M$1.2M$3.4M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001116463-26-000032.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M 600M Revenue, FY2016: 128.2M Gross profit, FY2016: 88M Net income, FY2016: 19.7M Revenue, FY2017: 167.1M Gross profit, FY2017: 99M Net income, FY2017: 30.9M Revenue, FY2018: 181.7M Gross profit, FY2018: 113.6M Net income, FY2018: 20.4M Revenue, FY2019: 154.6M Gross profit, FY2019: 94.6M Net income, FY2019: 16.7M Revenue, FY2020: 171.7M Gross profit, FY2020: 101.9M Net income, FY2020: -14.9M Revenue, FY2021: 233.7M Gross profit, FY2021: 117.6M Net income, FY2021: -23M Revenue, FY2022: 387.5M Gross profit, FY2022: 148.4M Net income, FY2022: -17.1M Revenue, FY2023: 405.5M Gross profit, FY2023: 171.7M Net income, FY2023: 53.7M Revenue, FY2024: 185.8M Gross profit, FY2024: 79.4M Net income, FY2024: -19.5M Revenue, FY2025: 115M Gross profit, FY2025: 48.2M Net income, FY2025: -68.7M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $128.2M $167.1M $181.7M $154.6M $171.7M $233.7M $387.5M $405.5M $185.8M $115.0M
Gross profit $88.0M $99.0M $113.6M $94.6M $101.9M $117.6M $148.4M $171.7M $79.4M $48.2M
Net income $19.7M $30.9M $20.4M $16.7M -$14.9M -$23.0M -$17.1M $53.7M -$19.5M -$68.7M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%